Telix Pharmaceuticals Limited
55 Flemington Road
About Telix Pharmaceuticals LimitedTelix Pharmaceuticals Limited is a new Australian (unlisted) public company that has been established to develop and commercialize several late-stage oncology assets. Our specialty area is “theranostic” radiopharmaceuticals – agents that are able to simultaneously image and treat cancer patients.
We are currently in “stealth mode” as we are currently closing several transactions. Please come back and check on us again soon. Feel free to contact us at email@example.com.
CEO: Dr. Christian Behrenbruch
21 articles with Telix Pharmaceuticals Limited
Heidelberg Pharma AG announced that it has received a milestone payment of 250 TUSD from its cooperation partner Telix Pharmaceuticals Limited, Melbourne, Australia,.
Telix Pharmaceuticals and Cardinal Health Enter into Distribution Agreement for Prostate Cancer Imaging
Telix Pharmaceuticals (US) Inc. today announced that it has entered into a distribution agreement with Cardinal Health (NYSE:CAH).
Heidelberg Pharma AG: Partner Telix Pharmaceuticals Files Phase III Trial for Kidney Cancer Imaging in Europe
Heidelberg Pharma AG (ISIN DE000A11QVV0 / WKN A11QVV / WL6) today announced that its partner Telix Pharmaceuticals Limited ("Telix") (ASX:TLX), has submitted a Clinical Trial Application (CTA) to initiate a Phase III trial in Europe for 89Zr-DFO-girentuximab (TLX250) for the imaging of renal (kidney) cancer with Positron Emission Tomography (PET).
Telix Pharmaceuticals Limited and Nihon Medi-Physics Co., Ltd. have today announced that they have entered into a memorandum of understanding (MOU) for a commercial partnership in renal cancer imaging for the Japanese market.
Telix Pharmaceuticals Limited is pleased to announce that Memorial Sloan Kettering Cancer Center (“MSK”) has imaged the first two patients in a 500 patient Phase II Expanded-Access Investigational New Drug (IND) study for imaging prostate cancer with the investigational agent 68Ga-PSMA-11
Telix Pharmaceuticals Limited has announced a technology transfer and manufacturing agreement with ISOLOGIC Innovative Radiopharmaceuticals
The purpose of the subsidiary is to support the Company’s Japanese clinical and radiopharmaceutical manufacturing activities and to establish a commercial footprint in the Japan, an important market for Telix’s products.
Telix Pharmaceuticals and Memorial Sloan Kettering Cancer Center Announce Renal Cancer Collaboration
The clinical objective is to use imaging as a precision medicine tool to rapidly determine an optimal therapeutic strategy for the patient.
JFE is an engineering and manufacturing company with extensive expertise in the installation of cyclotron infrastructure and radiopharmaceutical manufacturing in Japan.
Telix’s issue price is $65c per share, with a market capitalization of $128 million, placing the IPO as the largest for the Australian ASX biotechnology sector, by capital raised, since 1994.
The IPO was strongly supported by institutional investors internationally and domestically, as well as by retail investors in Australia.
The IPO is an offer by Telix for the issue of 77.0 million shares at $0.65 per share and is fully underwritten by the Lead Managers, Taylor Collison Limited and Wilsons Corporate Finance Limited
The agreement includes filing a Drug Master File (DMF) for the Kit, and completion of the necessary clinical trials to obtain marketing authorisation from the FDA.
University of Melbourne and Telix Pharmaceuticals Establish Cancer Translational Research Partnership
Novel technology discovered at University of Melbourne has the potential to transform the management of cancer.
Telix Pharma And Cellsight Technologies Conclude Collaboration And License Agreement For VisAcT ImmunoPET Technology
Cyclotek And Telix Pharma Conclude Radiopharmaceutical Manufacturing Agreement For Australia And New Zealand
Abzena And Telix Pharma Sign License Agreement For Abzena’s Prostate-Specific Membrane Antigen Antibodies
Telix Pharma, ATLAB Pharma Release: Companies Conclude Therapeutic Product Development Agreement For Prostate Cancer